The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice
|
|---|---|
| Published in |
Frontiers in Pharmacology, March 2019
|
| DOI | 10.3389/fphar.2019.00222 |
| Pubmed ID | |
| Authors |
Sílvia Castany, Xavier Codony, Daniel Zamanillo, Manuel Merlos, Enrique Verdú, Pere Boadas-Vaello |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 29% |
| Unknown | 5 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 57% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 24% |
| Researcher | 7 | 17% |
| Student > Bachelor | 5 | 12% |
| Student > Doctoral Student | 3 | 7% |
| Professor | 2 | 5% |
| Other | 3 | 7% |
| Unknown | 12 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 8 | 19% |
| Medicine and Dentistry | 8 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2019.
All research outputs
#6,969,790
of 23,136,540 outputs
Outputs from Frontiers in Pharmacology
#2,927
of 16,524 outputs
Outputs of similar age
#129,801
of 350,932 outputs
Outputs of similar age from Frontiers in Pharmacology
#142
of 344 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 16,524 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,932 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 344 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.